More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that can help people shed up to a fifth of their body weight. But these drugs promise to do more than boost drug companies’ profits. How will they reshape the economy?Hosts: Alice Fulwood, Mike Bird and Tom Lee-Devlin. Guests: The Economist’s Georgia Banjo; pharmaceuticals analyst Michael Nedelcovych; and John Cawley, a professor of public policy and economics at Cornell University.Sign up for our new weekly newsletter dissecting the big themes in markets, business and the economy at<a href="https://www.economist.com/moneytalks/?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source=moneytalks&utm_content=discovery.content.anonymous.tr_shownotes_na-na_article&utm_term=sa.listeners" rel="noopener noreferrer" target="_blank"> www.economist.com/moneytalks&nbsp;</a>Listen to what matters most, from global politics and business to science and technology—<a href="https://subscribenow.economist.com/podcasts-plus" rel="noopener noreferrer" target="_blank">subscribe to Economist Podcasts+</a>For more information about how to access Economist Podcasts+, please visit our<a href="https://myaccount.economist.com/s/article/What-is-Economist-Podcasts" rel="noopener noreferrer" target="_blank"> FAQs page</a> or watch<a href="https://www.youtube.com/watch?v=Gczo71bg1uY" rel="noopener noreferrer" target="_blank"> our video</a> explaining how to link your account.<hr> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Money Talks: Why weight-loss drugs will reshape the world

Money Talks from The Economist